Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
Returns on capital
Acumen Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-172.3%
avg -29.6%
ROIC
-121.7%
avg -54.3%
ROA
-98.8%
avg -49.8%
Analysis
ROA is currently the strongest return metric at -98.8% versus its period average of -49.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Daniel J. O'Connell | Chief Executive Officer & Director | USD 972.75K | 56 | — | — |
James Doherty | President & Chief Development Officer | USD 764.37K | 58 | — | — |
Derek Meisner | Chief Legal Officer & Corporate Secretary | USD 752.95K | 55 | — | — |
Matt Zuga | Chief Financial Officer & Chief Business Officer | USD 681.78K | — | 304.92K | 0.50% |
Russell Barton | Chief Operating Officer | USD 223.68K | 67 | 205.09K | 0.34% |
Grant A. Krafft | Co-Founder | USD 42K | — | — | — |
William L. Klein | Co-Founder | USD 42K | — | — | — |
Caleb E. Finch | Co-Founder | USD 42K | — | — | — |
Alex Braun | Vice President & Head of Investor Relations | — | — | — | — |
Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 22, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
48
$625,430.93
Net Transaction Value
−$625,430.93
Net selling
Most Active
Meisner Derek M
16 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 17, 26Jun 17, 2026 | Porter Derrell Direct | Sell | $30.3K$30,318.00 |
| Jun 16, 26Jun 16, 2026 | Porter Derrell Direct | Sell | $29.8K$29,772.80 |
| Jun 15, 26Jun 15, 2026 | Porter Derrell Direct | Sell | $15.1K$15,148.70 |
| Jun 9, 26Jun 9, 2026 | Fountain Nathan B Direct | Sell | $14.3K$14,272.64 |
| Mar 6, 26Mar 6, 2026 | Meisner Derek M Direct | Sell | $6.8K$6,813.40 |
| Feb 27, 26Feb 27, 2026 | Meisner Derek M Direct | Sell | $28.3K$28,311.12 |
| Jan 28, 26Jan 28, 2026 | Meisner Derek M Direct | Sell | $8K$8,017.27 |
| Jan 26, 26Jan 26, 2026 | Meisner Derek M Direct | Sell | $45.3K$45,262.54 |
| Jan 23, 26Jan 23, 2026 | Meisner Derek M Direct | Sell | $10.7K$10,717.91 |
| Jan 22, 26Jan 22, 2026 | OConnell Daniel Joseph Direct | Sell | $5.1K$5,065.54 |
1–10 of 48
Summary
Insiders reported 0 buys worth $0.00 and 48 sells worth $625,430.93 over the last 12 months. That adds up to net selling of $625,430.93. Meisner Derek M was the most active insider with 16 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Acumen Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ABOS's management, answered from reported figures.
Who manages ABOS?
Acumen Pharmaceuticals, Inc. (ABOS) lists 10 active executives. The top listed executive is Derek Meisner, Chief Legal Officer & Corporate Secretary.
Are ABOS insiders buying or selling?
Recent insider activity shows net buying of $74.71M.
Continue the stock analysis
Jump to another research area for this company.